Understanding the Pathogenesis and Management of Hepatitis B/HIV and Hepatitis B/Hepatitis C Virus Coinfection

Clinics in Liver Disease

Volumn 11, Issue 4, 2007, Pages 917-943

  Cheruvu, Srinivas ^a   Marks, Kristen ^a   Talal, Andrew H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN G; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR; VIRUS DNA; VIRUS VACCINE;

ANTIVIRAL ACTIVITY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE TRANSMISSION; DRUG APPROVAL; ENZYME BLOOD LEVEL; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; LIVER CELL CARCINOMA; LIVER FIBROSIS; OUTCOME ASSESSMENT; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS;

EID: 35548973775     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.08.007     Document Type: Review

References (139)

1. Peters M.G. Managing hepatitis B coinfection in HIV-infected patients. Curr HIV/AIDS Rep 2 3 (2005) 122-126
2. Hoofnagle J.H., Doo E., Liang T.J., et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45 4 (2007) 1056-1075
3. Alter M.J. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44 Suppl 1 (2006) S6-S9
4. UNAIDS. 2006 report on the global AIDS epidemic: a UNAIDS 10th anniversary special edition. Available at: http://www.unaids.org/en/HIV_data/2006GlobalReport/default.asp. Accessed March 22, 2007.
5. Bodsworth N.J., Cooper D.A., and Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 163 5 (1991) 1138-1140
6. Hadler S.C., Judson F.N., O'Malley P.M., et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 163 3 (1991) 454-459
7. Mast E.E., Weinbaum C.M., Fiore A.E., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR Recomm Rep 55 RR-16 (2006) 1-33
8. Des Jarlais D.C., Diaz T., Perlis T., et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol 157 5 (2003) 467-471
9. Bialek S.R., Bower W.A., Mottram K., et al. Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users. J Urban Health 82 3 (2005) 468-478
10. Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338 13 (1998) 853-860
11. Thio C.L., Seaberg E.C., Skolasky Jr. R., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360 9349 (2002) 1921-1926
12. Weber R., Sabin C.A., Friis-Moller N., et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166 15 (2006) 1632-1641
13. Konopnicki D., Mocroft A., de Wit S., et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 19 6 (2005) 593-601
14. Bonacini M., Louie S., Bzowej N., et al. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 18 15 (2004) 2039-2045
15. Salmon-Ceron D., Lewden C., Morlat P., et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 42 6 (2005) 799-805
16. Colin J.F., Cazals-Hatem D., Loriot M.A., et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 29 4 (1999) 1306-1310
17. Bodsworth N., Donovan B., and Nightingale B.N. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 160 4 (1989) 577-582
18. Gilson R.J., Hawkins A.E., Beecham M.R., et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 11 5 (1997) 597-606
19. Goldin R.D., Fish D.E., Hay A., et al. Histological and immunohistochemical study of hepatitis B virus in human immunodeficiency virus infection. J Clin Pathol 43 3 (1990) 203-205
20. Krogsgaard K., Lindhardt B.O., Nielson J.O., et al. The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers. Hepatology 7 1 (1987) 37-41
21. Carr A., and Cooper D.A. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 349 9057 (1997) 995-996
22. Piroth L., Grappin M., Buisson M., et al. Hepatitis B virus seroconversion in HIV-HBV coinfected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 23 4 (2000) 356-357
23. Bonacini M., Govindarajan S., and Redeker A.G. Human immunodeficiency virus infection does not alter serum transaminases and hepatitis B virus (HBV) DNA in homosexual patients with chronic HBV infection. Am J Gastroenterol 86 5 (1991) 570-573
24. Housset C., Pol S., Carnot F., et al. Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology 15 4 (1992) 578-583
25. Soriano V., Miro J.M., Garcia-Samaniego J., et al. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J Viral Hepat 11 1 (2004) 2-17
26. Puoti M., Torti C., Bruno R., et al. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 44 Suppl 1 (2006) S65-S70
27. Di Martino V., Thevenot T., Colin J.F., et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 123 6 (2002) 1812-1822
28. Lacombe K., Massari V., Girard P.M., et al. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS 20 3 (2006) 419-427
29. Altavilla G., Caputo A., Lanfredi M., et al. Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene. Am J Pathol 157 4 (2000) 1081-1089
30. Smukler A.J., and Ratner L. Hepatitis viruses and hepatocellular carcinoma in HIV-infected patients. Curr Opin Oncol 14 5 (2002) 538-542
31. Gomez-Gonzalo M., Carretero M., Rullas J., et al. The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals: functional roles of NF-kappaB/NF-AT and SP1-binding sites in the HIV-1 long terminal repeat promoter. J Biol Chem 276 38 (2001) 35435-35443
32. Law W.P., Duncombe C.J., Mahanontharit A., et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 18 8 (2004) 1169-1177
33. Iloeje U.H., Yang H.I., Su J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 3 (2006) 678-686
34. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 1 (2006) 65-73
35. Sheela H., Seela S., Caldwell C., et al. Liver biopsy: evolving role in the new millennium. J Clin Gastroenterol 39 7 (2005) 603-610
36. Zeremski M., and Talal A.H. Noninvasive markers of hepatic fibrosis: are they ready for prime time in the management of HIV/HCV co-infected patients?. J Hepatol 43 1 (2005) 2-5
37. de Ledinghen V., Douvin C., Kettaneh A., et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 41 2 (2006) 175-179
38. Mohamadnejad M., Montazeri G., Fazlollahi A., et al. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol 101 11 (2006) 2537-2545
39. Soriano V., Puoti M., Bonacini M., et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV international panel. AIDS 19 3 (2005) 221-240
40. Keeffe E.B., Dieterich D.T., Han S.H., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4 8 (2006) 936-962
41. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 2 (2007) 507-539
42. Alberti A., Clumeck N., Collins S., et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 42 5 (2005) 615-624
43. Benhamou Y., Fleury H., Trimoulet P., et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 43 3 (2006) 548-555
44. Dore G.J., Cooper D.A., Barrett C., et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 180 3 (1999) 607-613
45. Benhamou Y., Bochet M., Thibault V., et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30 5 (1999) 1302-1306
46. Hoff J., Bani-Sadr F., Gassin M., et al. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis 32 6 (2001) 963-969
47. Lim S.G., Ng T.M., Kung N., et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 166 1 (2006) 49-56
48. Hammer S.M., Saag M.S., Schechter M., et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296 7 (2006) 827-843
49. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents - October 10, 2006. Available at: http://aidsinfo.nih.gov. Accessed April 4, 2007.
50. Bessesen M., Ives D., Condreay L., et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 28 5 (1999) 1032-1035
51. Benhamou Y., Thibault V., Vig P., et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 44 1 (2006) 62-67
52. Gilleece Y., Nelson M., Clarke A., et al. Tenofovir in the treatment of hepatitis B/HIV coinfected individuals. [abstract #MoPeB3298]. Program and abstracts of the 15th International AIDS Conference (2004), International AIDS Society, Bangkok 55
53. Peters M.G., Andersen J., Lynch P., et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 44 5 (2006) 1110-1116
54. Sheldon J., Camino N., Rodes B., et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 10 6 (2005) 727-734
55. Locarnini S., Qi X., Arterburn A., et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). [abstract #36]. J Hepatol 42 S2 (2005) 17
56. Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 10 (2006) 1011-1020
57. Chang T.T., Gish R.G., de Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 10 (2006) 1001-1010
58. Colonno R.J., Rose R.E., Pokornowski K., et al. 4 year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. [abstract #781]. J Hepatol 46 Supp 1 (2007) S294
59. McMahon M.A., Jilek B.L., Brennan T.P., et al. The HBV drug entecavir-effects on HIV-1 replication and resistance. N Engl J Med 356 25 (2007) 2614-2621
60. Bristol-Myers Squibb. Important information regarding BARACLUDE® (entecavir) in patients co-infected with HIV and HBV. 2007. [Healthcare professional letter.]
61. Pessoa M., Gazzard B.G., Huang A., et al. Entecavir in HIV/HBV co-infected patients: safety and efficacy in a phase II study (ETV-038). [abstract #123]. Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (2005), Foundation for Retrovirology and Human Health, Boston 109
62. Pessoa M, Huang A, Nelson M, et al. Entecavir in HIV-HBV co-infection: week 48 results (ETV (038) [abstract H-415]. In: Program and abstracts of the 45th Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington, DC: 2005.
63. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 26 (2005) 2682-2695
64. Marcellin P., Lau G.K., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 12 (2004) 1206-1217
65. Mutimer D., Pillay D., Cook P., et al. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. J Infect Dis 181 2 (2000) 713-716
66. Dore G.J., Cooper D.A., Pozniak A.L., et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 189 7 (2004) 1185-1192
67. Schmutz G., Nelson M., Lutz T., et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 20 15 (2006) 1951-1954
68. Nelson M., Bhagani S., Fisher M., et al. A 48 week study of tenofovir (TDF) or lamivudine (LAM) or a combination of tenofovir and lamivudine for the treatment of chronic hepatitis B in HIV/hepatitis B co-infected individuals. [abstract #781]. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (2006), Foundation for Retrovirology and Human Health, Denver (CO) 353
69. Sheldon J.A., Corral A., Rodes B., et al. Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS 19 17 (2005) 2036-2038
70. Jain M.K., Comanor L., White C., et al. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepat 14 3 (2007) 176-182
71. Reisler R.B., Han C., Burman W.J., et al. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr 34 4 (2003) 379-386
72. Perrillo R.P. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120 4 (2001) 1009-1022
73. Jain M.K., Parekh N.K., Hester J., et al. Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs. AIDS Patient Care STDS 20 12 (2006) 817-822
74. Shimada N., Yamamoto K., Kuroda M.J., et al. HBcAg-specific CD8 T cells play an important role in virus suppression, and acute flare-up is associated with the expansion of activated memory T cells. J Clin Immunol 23 3 (2003) 223-232
75. Drake A., Mijch A., and Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis 39 1 (2004) 129-132
76. Liaw Y.F. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 22 4 Pt 1 (1995) 1101-1108
77. Jilg W., Sieger E., Zachoval R., et al. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol 23 1 (1995) 14-20
78. Hahn J.A., Page-Shafer K., Lum P.J., et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 186 11 (2002) 1558-1564
79. Bond W.W., Favero M.S., Petersen N.J., et al. Survival of hepatitis B virus after drying and storage for one week. Lancet 1 8219 (1981) 550-551
80. Krawczynski K., Alter M.J., Robertson B.H., et al. Environmental stability of hepatitis C virus (HCV): Viability of dried/stored HCV in chimpanzee infectivity studies. [abstract #556]. Hepatology 38 Suppl 4 (2003) 428A
81. Thorpe L.E., Ouellet L.J., Hershow R., et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 155 7 (2002) 645-653
82. Hagan H., Thiede H., Weiss N.S., et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 91 1 (2001) 42-46
83. Reddy G.A., Dakshinamurthy K.V., Neelaprasad P., et al. Prevalence of HBV and HCV dual infection in patients on haemodialysis. Indian J Med Microbiol 23 1 (2005) 41-43
84. Aroldi A., Lampertico P., Montagnino G., et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 79 9 (2005) 1132-1136
85. Irshad M., and Peter S. Spectrum of viral hepatitis in thalassemic children receiving multiple blood transfusions. Indian J Gastroenterol 21 5 (2002) 183-184
86. Zarski J.P., Bohn B., Bastie A., et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 28 1 (1998) 27-33
87. Fong T.L., Di Bisceglie A.M., Waggoner J.G., et al. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology 14 1 (1991) 64-67
88. Mohamed Ael S., al Karawi M.A., and Mesa G.A. Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. Hepatogastroenterology 44 17 (1997) 1404-1406
89. Kaklamani E., Trichopoulos D., Tzonou A., et al. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA 265 15 (1991) 1974-1976
90. Benvegnu L., Fattovich G., Noventa F., et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 74 9 (1994) 2442-2448
91. Chiaramonte M., Stroffolini T., Vian A., et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 85 10 (1999) 2132-2137
92. Donato F., Boffetta P., and Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 75 3 (1998) 347-354
93. Shi J., Zhu L., Liu S., et al. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 92 3 (2005) 607-612
94. Raimondo G., Brunetto M.R., Pontisso P., et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 43 1 (2006) 100-107
95. Crespo J., Lozano J.L., de la Cruz F., et al. Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am J Gastroenterol 89 8 (1994) 1147-1151
96. Liaw Y.F., Tsai S.L., Chang J.J., et al. Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis. Gastroenterology 106 4 (1994) 1048-1053
97. Chu C.M., Yeh C.T., and Liaw Y.F. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J Clin Microbiol 36 7 (1998) 2084-2086
98. Mimms L.T., Mosley J.W., Hollinger F.B., et al. Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. BMJ 307 6912 (1993) 1095-1097
99. Sagnelli E., Coppola N., Messina V., et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 36 5 (2002) 1285-1291
100. Liaw Y.F., Chen Y.C., Sheen I.S., et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 126 4 (2004) 1024-1029
101. Liaw Y.F., Lin S.M., Sheen I.S., et al. Acute hepatitis C virus superinfection followed by spontaneous HBeAg seroconversion and HBsAg elimination. Infection 19 4 (1991) 250-251
102. Dai C.Y., Yu M.L., Chuang W.L., et al. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 16 6 (2001) 636-640
103. Sheen I.S., Liaw Y.F., Lin D.Y., et al. Role of hepatitis C and delta viruses in the termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal follow-up study. J Infect Dis 170 2 (1994) 358-361
104. Utili R., Zampino R., Bellopede P., et al. Dual or single hepatitis B and C virus infections in childhood cancer survivors: long-term follow-up and effect of interferon treatment. Blood 94 12 (1999) 4046-4052
105. Shih C.M., Lo S.J., Miyamura T., et al. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol 67 10 (1993) 5823-5832
106. Schuttler C.G., Fiedler N., Schmidt K., et al. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 37 6 (2002) 855-862
107. Dumoulin F.L., von dem Bussche A., Li J., et al. Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral promoters in hepatic and nonhepatic cell lines. Virology 305 2 (2003) 260-266
108. Lin L., Verslype C., van Pelt J.F., et al. Viral interaction and clinical implications of coinfection of hepatitis C virus with other hepatitis viruses. Eur J Gastroenterol Hepatol 18 12 (2006) 1311-1319
109. Burt M.J., Chapman B.A., Scrimshaw B.J., et al. Concurrent hepatitis B and C infection treated successfully with alpha interferon. Aust N Z J Med 23 4 (1993) 411-412
110. Guptan R.C., Thakur V., Raina V., et al. Alpha-interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses. J Gastroenterol Hepatol 14 9 (1999) 893-898
111. Villa E., Grottola A., Buttafoco P., et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol 96 10 (2001) 2973-2977
112. Liaw Y.F., Chien R.N., Lin S.M., et al. Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. J Interferon Cytokine Res 17 8 (1997) 449-452
113. Weltman M.D., Brotodihardjo A., Crewe E.B., et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 2 1 (1995) 39-45
114. Zignego A.L., Fontana R., Puliti S., et al. Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. J Med Virol 51 4 (1997) 313-318
115. Liu C.J., Chen P.J., Lai M.Y., et al. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 37 3 (2003) 568-576
116. Hung C.H., Lee C.M., Lu S.N., et al. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol 20 5 (2005) 727-732
117. Chuang W.L., Dai C.Y., Chang W.Y., et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther 10 1 (2005) 125-133
118. Rautou P.E., Asselah T., Saadoun D., et al. Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-alpha2b plus ribavirin treatment in a patient with hepatitis B and C coinfection. Eur J Gastroenterol Hepatol 18 9 (2006) 1019-1022
119. Janssen H.L., van Zonneveld M., Senturk H., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 9454 (2005) 123-129
120. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 13 (2002) 975-982
121. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 9286 (2001) 958-965
122. Marrone A., Zampino R., D'Onofrio M., et al. Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection. J Hepatol 41 6 (2004) 1064-1065
123. Yalcin K., Degertekin H., Yildiz F., et al. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin. J Gastroenterol 38 8 (2003) 796-800
124. Cheruvu S., Beeder A.B., Carden M., et al. Strategies to control hepatitis C infection among injection drug users. In: Negro F. (Ed). Hot topics in viral hepatitis vol. 6 (2007), FB Communications, Modena (Italy) 23-28
125. Bhave G., Lindan C.P., Hudes E.S., et al. Impact of an intervention on HIV, sexually transmitted diseases, and condom use among sex workers in Bombay, India. AIDS 9 Suppl 1 (1995) S21-S30
126. Sanchez J., Gotuzzo E., Escamilla J., et al. Sexually transmitted infections in female sex workers: reduced by condom use but not by a limited periodic examination program. Sex Transm Dis 25 2 (1998) 82-89
127. Kellerman S.E., Hanson D.L., McNaghten A.D., et al. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 188 4 (2003) 571-577
128. Rey D., Krantz V., Partisani M., et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 18 13 (2000) 1161-1165
129. Laurence J.C. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 118 Suppl 10A (2005) 75S-83S
130. Tedaldi E.M., Baker R.K., Moorman A.C., et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 38 10 (2004) 1478-1484
131. Wiedmann M., Liebert U.G., Oesen U., et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 31 1 (2000) 230-234
132. Diaz B., Nunez M., and Soriano V. [Acute hepatitis B in a previously vaccinated patient infected by the human immunodeficiency virus]. Med Clin (Barc) 117 13 (2001) 518-519 [in Spanish]
133. Raimondo G., Pollicino T., Cacciola I., et al. Occult hepatitis B virus infection. J Hepatol 46 1 (2007) 160-170
134. Torbenson M., and Thomas D.L. Occult hepatitis B. Lancet Infect Dis 2 8 (2002) 479-486
135. Ikeda K., Marusawa H., Osaki Y., et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med 146 9 (2007) 649-656
136. Gandhi R.T., Wurcel A., Lee H., et al. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis 36 12 (2003) 1602-1605
137. Re III V.L., Frank I., Gross R., et al. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 44 3 (2007) 315-320
138. Shire N.J., Rouster S.D., Stanford S.D., et al. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr 44 3 (2007) 309-314
139. Filippini P., Coppola N., Pisapia R., et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 20 9 (2006) 1253-1260